Transaction Overview - Recursion and Exscientia are combining to bring better medicines to patients more rapidly and cost efficiently[11] - Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share[27] - Recursion shareholders will own approximately 74% of the combined company, while Exscientia shareholders will own approximately 26%[27] - The transaction is expected to close by early 2025, subject to shareholder approvals and closing conditions[27] Financial Synergies and Cash Position - The combined company will have approximately $850 million in cash as of the end of Q2 2024[11, 27] - Estimated annual synergies of $100 million or more are expected[11, 27] - The pro forma combined financial plans are expected to extend the cash runway into 2027[27] Pipeline and Partnerships - The combined company anticipates approximately 10 clinical readouts over the next 18 months[11, 12, 14] - Current partnerships have the potential for over $200 million in milestone payments over the next 2 years[11, 18] - The combined company has the potential for over $20 billion in total revenue before royalties from partners[18] - CDK4/6 inhibitors generated $11 billion in sales in 2023[31]

Recursion Pharmaceuticals (RXRX) Q4 2024 Earnings Call February 28, 2025 08:30 AM ET Company Participants Chris Gibson - Co-Founder & CEOLina Nilsson - SVP Head of PlatformBen Taylor - CFO & President Recursion UK Chris Gibson Welcome everybody to Recursion's learnings call. I'm Chris Gibson, cofounder and CEO, and I'm excited to take you through Recursion's twenty twenty four, twenty twenty five, and the time ahead. So with that, we'll jump into the slides. And I wanna just set the stage, first of all, to ...